AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03649698 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-quality protein supplement
Description: The participant will receive an individually adapted protein supplement to achieve the recommend total (usual diet and supplements) daily intake of 1.5 g/protein/kg for frail elderly. This will be realized by adding an individualized amount (g) of protein powder during breakfast, lunch, dinner or snack between meals, or before breakfast or after dinner, based on the subjects' food intake assessed by a food diary. The participant will take the protein supplement from 5 days before the start of the intervention. The protein powder is commercially available and consists of 4.5g protein/5g powder. During the follow-up, no protein supplement is added.
Study NCT03649698 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid
Description: Four weeks before the start of the intervention, the participant will start the intake of 1 omega-3 capsule providing in total 500 mg EPA and 450 mg DHA until the end of the intervention. He or she has to take the supplement once daily at a chosen time. During the follow-up, no omega-3 supplement will be given.
Study NCT03649698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo protein powder
Description: Isocaloric maltodextrin powder. Amount based on food diary.
Study NCT03649698 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo protein powder
Description: Isocaloric maltodextrin powder. Amount based on food diary.
Study NCT03649698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo omega-3
Description: Peanut oil soft gel capsules. 1g/ capsule. 1 capsule/day
Study NCT03813472 — intervention group
Intervention type: DEVICE
Intervention: Hydration Sensor
Description: This device includes a hydration sensor embedded within silicone and applied to the skin with a medical grade adhesive.
Study NCT01413100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01413100 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study NCT01413100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01413100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO
Study NCT01413100 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo autologous PBSCT
Study NCT01413100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Given SC
Study NCT01413100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01413100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00570791 — intervention group
Intervention type: DEVICE
Intervention: Tonometer
Description: Tonometer devices used to measure IOP: Pascal Dynamic Contour Tonometer, Goldman Applanation Tonometer, Tono Pen, Reichart pneumatonometer, Langham Ocular Blood Flow, Schiotz Tonometer and ICare tonometer
Study NCT03368963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoliposomal Irinotecan
Description: Given IV
Study NCT03368963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine and Tipiracil Hydrochloride
Description: Given PO
Study NCT03658200 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FAST start software delay
Description: Scan delay will be determined by the FAST software bolus tracking technique. Before the start of bolus tracking (the time between start injection and start bolus tracking), a delay of 8 s is chosen. Bolus tracking threshold is set at 100 HU with a cycle time of 1.13 s and scan time of 0.25 s. After reaching the 100 HU threshold the FAST START software calculates the delay.
Study NCT03658200 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual bolus tracking delay
Description: Scan delay will be determined by the standard bolus tracking technique. Before the start of bolus tracking (the time between start injection and start bolus tracking), a delay of 8 s is chosen. Bolus tracking threshold is set at 100 HU with a cycle time of 1.13 s and scan time of 0.25 s. After reaching the 100 HU threshold a delay of 6 s is chosen (table movement and breath hold command) and the scan starts.
Study NCT03102047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: Within 3-7 days after completion of chemoradiation, patients will receive durvalumab (750 mg IV infusion) every 2 weeks for 4 doses on Day 1(Dose 1), Day 15 (Dose 2), Day 29 (Dose 3), and Day 43 (Dose 4)
Study NCT01632475 — intervention group
Intervention type: BIOLOGICAL
Intervention: Pneumostem®
Description: A single intratracheal administration~Low Dose Group (3 patients): 1.0 x 10\^7 cells/kg, High Dose Group (6 patients): 2 x 10\^7 cells/kg~\* The subjects were administered with Pneumostem® in the earlier part of the phase I study. No drugs/biologics are administered during this part of the study.
Study NCT01872195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The comprehensive patient safety checklist system
Description: The comprehensive patient safety checklist system follows each patient from admission to discharge with separate short checklists at each point of care: On admission to the hospital and ward (operating theatre nurse, ward doctor, surgeon, anaesthesiologist, ward nurse - 5 lists), in the operating theatre (here covered by the WHO-Safe Surgery checklist), at the recovery/ICU unit (nurse- 1 list), at discharge from the hospital (ward doctor, ward nurse - 2 lists).
Study NCT03923621 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EPSiT
Description: Specialised fistuloscope to indentify sinus tracts, cautery tracts, remove causative hair, irrigation.
Study NCT03923621 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Excision
Description: Surgery to remove all affected tissue, followed by wound closure.
Study NCT04131387 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIPUS-1
Description: After installing the disposable treatment head coat, the pelvic floor muscles, ligaments, etc. were treated with an ultrasonic therapeutic apparatus; after the treatment, the disposable treatment head coat was removed. Treated twice a week for 6 weeks.
Study NCT04131387 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: LIPUS-2
Description: The placebo was treated with an ultrasound therapy device and used in the same manner as the test group.
Study NCT04527237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure
Description: The person will be given 2 applications a day at 12-hour intervals and 6 applications in 72 hours in total. The session duration of an individual will be approximately 25 minutes.~Physiological measurements will be made before and after the acupressure application. Physiological measurements 10-15 min. From acupressure application. will be taken before and the same measurements after acupressure 20-30. Will be taken again in the min interval. In addition, the Continuous Anxiety Scale will be applied once before application, the State Anxiety Scale will be applied once before the application and 3 times in total after the application at the end of every 24 hours. Sleep Scale will be applied 3 times in total before the next day after application.
Study NCT04527237 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Unlike acupressure, it will only be in contact with gloves, to reduce the electrical effect of touch, away from the actual acupressure points.
Study NCT02934880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immediate APA program
Description: 10 sessions of one hour APA in 5 weeks after patient randomization. 2 sessions per week will be organized
Study NCT02934880 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: delayed APA program
Description: 10 sessions of one hour APA in 5 weeks 3 months after patient randomization. 2 sessions per week will be organized
Study NCT00605098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir / ritonavir
Description: Lopinavir/r (200/50 mg, 2 tablets every 12 hours) plus two nucleoside analogs, starting at any time between 14 and 30 weeks of gestation and maintained for at least 6 weeks after delivery.
Study NCT00605098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: Lopinavir/r (200/50 mg, 2 tablets every 12 hours) plus two nucleoside analogs, starting at any time between 14 and 30 weeks of gestation, increase the lopinavir/r dosage (200/50 mg, 3 tablets every 12 hours) in the third trimester (from 25 weeks on), and return to standard dose(200/50 mg, 2 tablets every 12 hours)for at least 6 weeks after delivery.
Study NCT00758264 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: Single dose intramuscular injection.
Study NCT00758264 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal vaccine GSK134612
Description: Single dose intramuscular injection.
Study NCT00758264 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK1024850A
Description: Single dose intramuscular injection.
Study NCT00758264 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal vaccine GSK1024850A
Description: Single dose intramuscular injection.
Study NCT04434625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol
Description: Before colonoscopy, patient-related and procedure-related parameters were collected by one investigator in each center. In MI group, a procedure-based score, used for predicting inadequate bowel preparation, was calculated for each patients. Patients with score ≥3 were asked to taking another dose of PEG (1.5L) within 1-2 hours. Colonoscopy was performed in afternoon (about 4h after drinking PEG). Patients with score\<3 in IM group and those in the control group underwent colonoscopy directly
Study NCT00201448 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A Vaccine
Description: Single dose give IM
Study NCT00201448 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Towne CMV Vaccine
Description: Single dose given subcutaneously
Study NCT04392141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: Standard Treatment for COVID-19 based on National Recommendations
Study NCT04392141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions
Description: Colchicine plus a Herbal extraction containing a Phenolic Monoterpene Fractions will be added to standard treatment in patients with COVID-19.
Study NCT02754141 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986179
Description: Specified dose on specified days
Study NCT02754141 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT02754141 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: Specified dose on specified days
Study NCT04114643 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prothrombin Complex Concentrate
Description: Octaplex will be administered when the blood bank receives an order for coagulation factor replacement
Study NCT04114643 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Frozen Plasma
Description: Frozen Plasma will be administered when the blood bank receives an order for coagulation factor replacement
Study NCT01562522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological counseling
Description: Attendance at 7 group sessions, consisting of 5-6 couples, preceded by an intake consultation. Total intervention time: 16 weeks.
Study NCT03894631 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: KDB/Phacoemulsification
Description: 50 eyes of 50 patients will receive combined KDB/phaco surgery
Study NCT03894631 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabectome/Phacoemulsification
Description: The contralateral 50 eyes of the same 50 patients will receive combined Trabectome /phaco surgery
Study NCT05280002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adipose Tissue derived Total-Stromal-Cells (TOST)
Description: Single dose autologous aAdipose Tissue derived Total-Stromal-Cells (TOST) containing mesenchymal stem cell was injected in each knee of the participants having knee osteoarthritis.
Study NCT01498575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teen driving plan
Description: Web-based intervention designed to facilitate parent supervised practice driving with novice teen driver.
Study NCT02007057 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block
Study NCT02007057 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene nerve block
Study NCT03652857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Combined With Vinorelbine
Description: Vinorelbine 60mg/m2 d1qweek , Apatinib 500mg po Qd,evaluate every 2months
Study NCT00368836 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreathScreen PE
Description: One minute of breath collection by tidal breathing into the BreathScreen PE and blood draw for D-dimer level
Study NCT01296633 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medtable
Description: Nurse works with patient to reconcile EMR-based medication list and load list into Medtable. Nurse uses Medtable with patient to develop plans for taking medications. Patient completes Medtable columns to identify when routine activities are performed during the day. Nurse discusses medications with patient: what the medication is called, used for, etc. Nurse and patient jointly develop the schedule by choosing times to take each medication. These times are entered into corresponding cells of the Medtable. Nurse corrects any mistakes (e.g., times that would conflict with dose spacing requirements). Nurse asks patient to review to ensure patient understands key facts and that drug interactions or other restrictions are addressed, using collaborative inquiry, teach-back, and teach-to-goal strategies. Patient takes home a hardcopy of the Medtable schedule to guide adherence. An updated e-copy is integrated with patient's record in the EMR.
Study NCT01296633 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medtable
Description: Nurse works with patient to reconcile EMR-based medication list and load list into Medtable. Nurse uses Medtable with patient to develop plans for taking medications. Patient completes Medtable columns to identify when routine activities are performed during the day. Nurse discusses medications with patient: what the medication is called, used for, etc. Nurse and patient jointly develop the schedule by choosing times to take each medication. These times are entered into corresponding cells of the Medtable. Nurse corrects any mistakes (e.g., times that would conflict with dose spacing requirements). Nurse asks patient to review to ensure patient understands key facts and that drug interactions or other restrictions are addressed, using collaborative inquiry, teach-back, and teach-to-goal strategies. Patient takes home a hardcopy of the Medtable schedule to guide adherence. An updated e-copy is integrated with patient's record in the EMR.
Study NCT01467037 — intervention group
Intervention type: OTHER
Intervention: No intervention done
Description: Not applicable because no intervention was done.
Study NCT00820794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: 300 mg lithium, oral, once initially and then again at day 4 of PD 0332334 treatment
Study NCT00820794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332334
Description: 225 mg q12h PD 0332334, oral, 9 days treatment
Study NCT00820794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: 300 mg lithium, oral, at day 4 of PD 0332334 treatment and after 7 day washout
Study NCT01345591 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat Grafting
Study NCT05332587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: The therapeutical schema is rituximab 100-200 mg/week for a total of 2-4 times
Study NCT01571128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Male-Specific Intervention Package
Description: Combination HIV Prevention: Male-Specific Intervention Package at the Mobile Health events and longitudinal follow up of cohorts.
Study NCT01571128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Female-Specific Intervention Package
Description: Combination HIV Prevention: Female-Specific Intervention Package at the Mobile Health events and longitudinal follow up of cohorts.
Study NCT01571128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Exposure Prophylaxis (Females)
Description: Females 18-24 who are out of school.
Study NCT01571128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cash Transfer Cohort (Females)
Description: Cash transfer for females (and their parents) who are aged 15-24 and enrolled in school.
Study NCT04243018 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy Group Treatment
Description: The intervention presents, a mixture of instruction, discussion, and the use of metaphor and experiential activities designed to sensitise participants to the effects of self-stigma and shame on how they live their lives. This training condition provides instruction and experiences that train participants to notice, and then to override, the very human tendency to categorise and then avoid aversive thoughts and feelings and the people and situations that evoke them. The acceptance and commitment training condition will cover the following topics: (a) introduction to enacted and self-stigma (b) cognitive defusion/behavioural flexibility (c) acceptance vs. avoidance and control of emotions and thoughts and (d) values and committed action.
Study NCT04243018 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer Support Group
Description: The peer support group will allow participants to share and discuss experiences related to their experiences of homelessness, shame and stigma. The group will be facilitated by an expert in facilitating peer support groups with marginalised populations.
Study NCT02121392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: In the functioning continuous adductor canal block, 0.125% bupivacaine will be infused at a rate of 8cc/hr.
Study NCT02121392 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Bupivacaine
Description: In the functioning continuous adductor canal block, 0.125% bupivacaine will be infused at a rate of 8cc/hr.
Study NCT03649698 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo omega-3
Description: Peanut oil soft gel capsules. 1g/ capsule. 1 capsule/day
Study NCT00873756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: Intravenous repeating dose
Study NCT00873756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenous repeating dose
Study NCT00873756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dulanermin
Description: Intravenous repeating dose
Study NCT01635972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: oral
Study NCT01635972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion hydrochloride
Description: oral
Study NCT02228785 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G17DT
Study NCT03227029 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV ΔNS2/Δ1313/I1314L
Description: 10\^6 plaque-forming units (PFU); administered as nose drops
Study NCT03227029 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV 276
Description: 10\^5 PFU; administered as nose drops
Study NCT03227029 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isotonic diluent, administered as nose drops
Study NCT00292695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VP-16, Cisplatin, Ifosfamide, Dexamethosone, Mesna, IF-RT
Description: IF-RT 50.4 Gy/28 Fractions, DEP: (Q4W, CCRT) X 2 Dexamethosone 20 mg/m2/d iv D1-3 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-3 Cisplatin 75 mg/m2 ivd 4 hr D1~DVIP: (Q4W, POST-RT) X 2 Dexamethosone 20 mg/m2/d iv D1-4 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-4 Ifosfamide 1.2 gm/m2/d ivd 2 hr D1-4 Mesna 240 mg/m2/d iv at 0, 4, 8 hr D1-4 Cisplatin 20 mg/m2 ivd 1 hr D1-4 G-CSF 250ug subcut D 9-12
Study NCT05263323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient education
Description: Providing patient education to hemodialysis patients according to Neuman Systems Model by the researcher.
Study NCT05263323 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data Collecting, No Education
Description: Data were collected at the beginning and end of the study without training the control group.
Study NCT03182101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Therapy
Description: Exposure Therapy is a form of Cognitive Behavioral Therapy. There is strong evidence for exposure as a necessary and primary ingredient for treating anxiety and OCD, and exposure is the most common practice element in treatment protocols for anxiety.